AbCellera Biologics Inc. Total Liabilities
AbCellera Biologics Inc. (ABCL) had Total Liabilities of $411.56 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-08-05
- 2026-06-30: Liabilities $411.56M.
- 2026-03-31: Liabilities $369.03M.
- 2025-12-31: Liabilities $390.05M.
- 2025-09-30: Liabilities $391.95M.
| Period end | Liabilities |
|---|---|
| 2026-06-30 | $411.56M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $369.03M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $390.05M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $391.95M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $394.99M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $321.23M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $304.47M 10-K · filed 2026-02-24 |
| 2024-09-30 | $314.73M 10-Q · filed 2024-11-04 |
| 2024-06-30 | $301.51M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $333.18M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $335.78M 10-K · filed 2025-02-27 |
| 2023-09-30 | $329.42M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $342.34M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $289.42M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $307.63M 10-K · filed 2024-02-20 |
| 2022-09-30 | $302.24M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $380.93M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $384.78M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $292.84M 10-K · filed 2023-02-21 |
| 2021-09-30 | $219.34M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $184.18M 10-Q · filed 2021-08-13 |
| 2021-03-31 | $171.40M 10-Q · filed 2021-05-14 |
| 2020-12-31 | $175.03M 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |